Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
7
|
pubmed:dateCreated |
1988-8-22
|
pubmed:abstractText |
A phase II study of FT-207 suppository (Futraful Suppository) for head and neck cancer was conducted at the Kagoshima University Hospital Dept. of Otorhinolaryngology and its 6 affiliated hospitals. Forty cases with head and neck cancer were entered in the trial, of which 37 were perfectly evaluable. Partial response (PR) (16.7%) was achieved in one of 6 patients with maxillary cancer, in 2 of 9 cases with oral cancer (22.2%), in one of 7 with laryngeal cancer (14.3%), in 3 of 13 with pharyngeal cancer, while 2 of the same 13 achieved a complete response (CR) (38.5%), for a total response rate of 24.3%. FT-207 suppository was continuously administered as standard, at a dose of 750 mg each twice daily, or 1,500 mg/day. The response rate was dose-dependent; 2 CR cases with a total dose of 105 g for administration over a total period of more than 150 days. Adverse effects appearing in 35.0% of the overall were mainly anorexia, nausea and vomiting; none of them, however, were serious.
|
pubmed:language |
jpn
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0385-0684
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
15
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
N
|
pubmed:pagination |
2093-100
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:3134860-Aged,
pubmed-meshheading:3134860-Anorexia,
pubmed-meshheading:3134860-Carcinoma, Squamous Cell,
pubmed-meshheading:3134860-Dose-Response Relationship, Drug,
pubmed-meshheading:3134860-Drug Evaluation,
pubmed-meshheading:3134860-Female,
pubmed-meshheading:3134860-Head and Neck Neoplasms,
pubmed-meshheading:3134860-Humans,
pubmed-meshheading:3134860-Male,
pubmed-meshheading:3134860-Maxillary Sinus Neoplasms,
pubmed-meshheading:3134860-Middle Aged,
pubmed-meshheading:3134860-Nausea,
pubmed-meshheading:3134860-Remission Induction,
pubmed-meshheading:3134860-Suppositories,
pubmed-meshheading:3134860-Tegafur,
pubmed-meshheading:3134860-Vomiting
|
pubmed:year |
1988
|
pubmed:articleTitle |
[A phase II study of Futraful suppository in head and neck cancer].
|
pubmed:affiliation |
Dept. of Otorhinolaryngology, Kagoshima University Hospital.
|
pubmed:publicationType |
Journal Article,
English Abstract,
Case Reports
|